Effective diabetes pill may increase bladder and breast cancer risk
Jul 28, 2011
In breast cancer health news, dapagliflozin, a new diabetes pill awaiting approval, may face some roadblocks, as a study shows it has the potential to lead to bladder and breast cancer.
According to Medical News Today, the U.S. Food and Drug Administration (FDA) is pondering whether or not to approve dapagliflozin. The clinical trials of the drug revealed more cases of bladder and breast cancer among patients receiving dapagliflozin than those who received placebos.
Nine cases of both bladder and breast cancer were found among dapagliflozin patients, compared to one case of each among people who received placebos.
FDA reviewers wrote in their report, "Several unexpected safety issues identified in this clinical development program were of sufficient concern to FDA to merit discussion of their impact on the overall benefit-risk consideration of dapagliflozin."
The news source reports that experts expect the FDA to request more proof of the effectiveness of the drug before a decision is made.
The risk factors of breast cancer include age, genetics, family history, race, breast tissue density and other certain breast conditions, according to the American Cancer Society. Being a woman raises the risk of breast cancer, as women are about 100 times more likely to develop the disease than men.